Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Gap Down - Here's What Happened

Key Points

• Eupraxia Pharmaceuticals shares opened lower, falling from the prior close of $8.42 to $8.05 and last trading at $8.01 on volume of 16,943 shares.
• Analyst views remain mixed, but the stock carries a consensus “Moderate Buy” rating and an average price target of $18.00, well above its recent trading level.
• The company reported a quarterly loss of $0.23 per share, beating estimates by $0.02, while several institutional investors—including Seven Fleet Capital, Bank of America and Jupiter Topco—recently initiated positions.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $8.42, but opened at $8.05. Eupraxia Pharmaceuticals shares last traded at $8.01, with a volume of 16,943 shares.

Analysts Set New Price Targets

Several analysts have commented on EPRX shares. Wall Street Zen raised Eupraxia Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday. Oppenheimer began coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They issued an "outperform" rating and a $17.00 target price on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Stifel Nicolaus started coverage on Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They set a "buy" rating and a $25.00 price target for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Eupraxia Pharmaceuticals Stock Up 0.6%

The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $527.95 million, a PE ratio of -7.96 and a beta of 1.07. The firm's fifty day moving average is $6.87 and its 200-day moving average is $6.99.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. On average, equities research analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of EPRX. AXQ Capital LP raised its position in Eupraxia Pharmaceuticals by 34.2% in the second quarter. AXQ Capital LP now owns 21,150 shares of the company's stock worth $140,000 after acquiring an additional 5,390 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth $4,037,289. Bank of America Corp DE acquired a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth $1,750,000. Jupiter Topco LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $6,851,000. Finally, Cibc World Market Inc. purchased a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $1,539,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc NASDAQ: EPRX is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients' exposure to medication throughout the body.

Eupraxia's development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects.

The company's lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.